65,437 trials
Metabolic Syndrome
Primary: Ex Vivo Effects of Treatment With Vytorin Versus Zocor for 6 Weeks on Platelet Alpha Thrombin PAR-1 Receptor Expression — 35.4; 34.5; 23.6; 22.5 ng/dl
Pre-diabetic State · Overweight · Obesity
Primary: Weight Loss — 4.37; 3.23 kilograms
Anxiety
Primary: Change From Baseline at 8 Weeks in the HAM-A Scale — 6.12 units on a scale
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
Cardiac Transplantation
Primary: Participants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group — 40; 30 participants — p=0.1043
Drug Addiction
Primary: Emotional Recognition (MDMA) — 55.9 percent intensity
Fibromyalgia, Primary
Primary: Brief Fatigue Inventory — 2.86; 4.29 units on a scale — p=<0.05
Adenocarcinoma of the Prostate · Stage IV Prostate Cancer
Primary: Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at End of 7 Cycles — 22 percentage of participants
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 16350.6; 23806.5; 976.9; 954.3 ng/mL
Hypertension
Primary: Blood Pressure Change — 148; 147; 79; 79 mmHg
Postoperative Pain
Primary: Pain Scores, Visual Analogue Pain Scale — 2.75 units on a scale
Depressive Disorder · Depression
Primary: Change in Severity of Depression Using Hamilton Depression Rating Scale — 20.83; 19.23; 16.71; 17.27 units on a scale — p==.001
Breast Cancer
Primary: Phase II: The Number of Subjects Exhibiting Pathologic Complete Response to Neoadjuvant Treatment With Sunitinib/Paclitaxel/Carboplatin — 12 participants
Disorder of Soft Tissue
Primary: Assessment of Treatment Site Responses Post Procedure — 78 percentage of participants with any AE
Efavirenz, Metabolism and Pharmacokinetics Changes
Primary: Measure Efavirenz Clearance — 45.51; 20.03 ml/min/kg